Management of oral stomatitis associated with BRAFi-MEKi therapy using intralesional corticosteroid and local anesthetic: a case report.
Maria Cecilia Querido de Oliveira, Maria Cláudia Cuzzullin, Vallentine Louzada Miranda et al.
✦ AI-curated · Sources linked
Case in brief
A 66-year-old woman with a history of choroidal melanoma developed a fibrinopurulent ulcer on the tongue after starting dabrafenib-trametinib therapy for tumor recurrence. Initial biopsies showed inflammation without malignancy. The diagnosis of stomatitis related to BRAFi-MEKi therapy was made. Treatment with intralesional corticosteroids and local anesthetics led to complete healing of the lesion within two months.
What made this case unusual
This case presents a previously unreported oral adverse event associated with combined BRAFi-MEKi therapy, emphasizing the need for awareness of such toxicities.
Diagnostic / clinical pearl
Clinicians should be vigilant for unusual oral toxicities in patients receiving BRAFi-MEKi therapy, as timely recognition and management can facilitate ongoing oncologic treatment.
Why it matters
Understanding the spectrum of adverse effects from targeted therapies is crucial for optimizing patient care and treatment adherence.